Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change. To learn more, view Big Ideas 2023. This week’s Big Ideas Monday Mini Episode focuses on Digital Consumers. In 2022, digital leisure spending* totaled $6.6 trillion and, during the next eight years, should grow 17% at a compound annual rate to $22.5 trillion adjusted for inflation. Four trends should contribute to its growth: Connected TV (CTV): Roughly 85% of US households have access to at least one CTV, but the CTV ad market is only 23% the size of total US TV ad budgets. In our view, CTV is at an inflection point and will take share from both linear TV and other digital ad budgets. New Social Platforms: Nearly 40% of Gen Z consumers prefer to search on TikTok and Instagram over Google Search and Maps. Social platforms with the best recommendation engines should command the majority of ad budgets, with content-based social media likely outperforming follow-and-feed social media. Sports Betting: Despite macro headwinds, consumer demand for sports betting remains strong. Legalization of online/mobile sports betting should continue to catalyze growth. Gaming: The convergence of video games and social media should sustain gaming revenue growth. Video games should provide end-to-end virtual entertainment that rivals physical experiences. Watch the video version here. *We define digital leisure spending as the sum of consumer expenditures on leisure-related goods and services purchased online, NFTs, online sports betting, video game software and services, streamed video, and streamed audio. We only estimate online sports betting volume generated in Canada and the US. Sources: ARK Investment Management LLC, 2023. Altruda, C. 2022; Roblox, data as of 12/30/22; S&P Global Market Intelligence, data as of 01/25/23. The World Bank, data as of 12/30/22; Insider Intelligence, data as of 01/02/23; S&P Global Market Intelligence, data as of 01/25/23; Perez, S. 2022; Statista, data as of 01/25/23. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.

Immunotherapy has the potential to cure cancer. Today we are joined by a leading figure in cancer studies and research and one who has helped shape the immunotherapy landscape, Dr. Patrick Hwu. The internationally recognized Dr. Hwu previously applied his trade at the National Cancer Institute and is now the President and CEO of one of America’s leading cancer hospitals, the Moffitt Cancer Center. We tap into Dr. Hwu’s wealth of knowledge and experience as he explains what immunotherapy is, its benefits, and how it differs from other cancer treatments. We explore the recent advancements in immunotherapy and what the future of this treatment looks like, why the time to market for new technologies and therapies needs to improve and how the FDA fits in, how to get the right treatments to the right patients at the right time, and how Dr. Hwu and his team are impressing the industry with the way they use math, data aggregation, and large language models (LLMs) to problem-solve. We end with some heartfelt stories of triumph from Dr. Hwu’s career, the hand he’s played in building Florida’s formidable biotech ecosystem, and his words of inspiration for future scientists and a message of hope for families who are currently fighting through treatment. We have to, as a society, continue to shrink that time between the lab idea, the clinical trial, and the FDA approval for drugs that can really save lives.” — @PatrickHwuMD Key Points From This Episode: Joining us today is the President and CEO of Moffitt Cancer Center, Dr. Patrick Hwu. Background on Dr. Hwu’s professional career. What immunotherapy is, its benefits, and how it differs from traditional cancer treatments. How Dr. Hwu helped shaped the immunotherapy landscape: his ‘aha’ moments. Exciting advancements going on in his lab and immunotherapy in general. Dr. Hwu explains he’s having a lot of fun working with CRISPR for gene editing. Why FDA regulations need to be adjusted to accommodate new technologies and treatments. How to lower the costs of cell and other important therapies, and why this needs to happen. Why resources like ClinicalTrails.gov need to be more abundant. Examining why some patients respond better to gene therapy than others. How to improve the process of getting the right drug to the right patient at the right time. The impressive way that Dr. Hwu and his team utilize math, data aggregation, and LLMs. Assessing the challenge of persistence in immunotherapy. Inspirational stories of triumph from Dr. Hwu’s career. Revisiting more ways to shorten the time to market for new technologies and therapies. Playing piano for two bands, and other ways that Dr. Hwu lets off steam. How he’s contributed to building an impressive biotech ecosystem in Florida. Advice for potential immunotherapy scientists, and words of hope for families in therapy.

Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change. To learn more, view Big Ideas 2023. This week’s Big Ideas Monday Mini Episode focuses on 3D Printing and Robotics. Robotics and 3D printing can collapse time from development to production, shorten supply chain footprints, reduce waste, and lower costs. ARK estimates that manufacturing robots and 3D printing could scale at a ~80% annual rate during the next eight years, from $70 billion in 2022 to ~$9 trillion by 2030. Watch the video version here. Sources: ARK Investment Management LLC, 2023. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.

According to Dr. Arthur Laffer, since 1913, when the United States first imposed the income tax via constitutional amendment, the top rate of that tax has determined the fate of the American economy. When the top rate has been high, as in the late 1910s, the 1930s, 1940s, 1950s, and 1970s, the response of those with money and capital has been to curtail real economic activity in favor of protecting assets and income streams. Huge declines have come to the economy in these circumstances. On today’s podcast, ARK CEO, CIO and Founder Cathie Wood is again joined by Dr. Arthur Laffer, a famed economist, well-known for his creation of “The Laffer Curve,” so Dr. Laffer and Cathie can discuss Laffer’s book, Taxes Have Consequences, in which Dr. Laffer provides a history of taxes and their impact on the United States economy. Dr. Laffer explains why he believes that a low rate broad-based flat tax, spending restraint, sound money, minimal regulations, and free trade are the answers to most of our economic problems. “Low rate broad-based flat tax, spending restraint, sound money, minimal regulations, and free trade, and then get the hell out of the way and let markets solve it.” — Arthur Laffer Key Points From This Episode: An overview of Arthur Laffer’s new book, Taxes Have Consequences. How the government finances taxation. A history of income tax since 1913. Defining characteristics of the Roaring Twenties. The market collapse that occurred in 1929. Similarities between the environment in 1929 and today. How Art would structure the American tax system if he could. Why stimulus spending hurts the economy. Art’s thoughts on regulation. Why Art is a strong proponent of developing free trade agreements with countries that the US currently has issues with. What makes America different from the rest of the world. The correlation between tax hikes and economic performance. Why everyone benefits in a low rate broad-based flat tax system. The role of taxes in the Great Depression. Factors that Art attributes the high inflation levels to. The importance of acting fast when it comes to changing policies around taxes. How the pandemic has accelerated the migration to low tax states. Interesting statistics about states like Texas, Florida and Tennessee. Art’s thoughts on how to address poverty in the United States.

Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change. To learn more, view Big Ideas 2023. This week’s Big Ideas Monday Mini Episode focuses on Digital Wallets. Having onboarded billions of consumers and millions of merchants, digital wallets could transform the economics associated with traditional payment transactions, saving them nearly $50 billion in costs. With 3.2 billion users, digital wallets have penetrated 40% of the global population. ARK research suggests that the number of digital wallet users will increase 8% at an annual rate, penetrating 65% of the global population by 2030. As consumers and merchants adopt digital wallets, the usage of traditional checking accounts, credit and debit cards, and direct merchant accounts should decline, disrupting traditional payment intermediaries. Cutting out middlemen, digital wallets could facilitate closed-loop transactions for more than 50% of their payment volumes, potentially adding $450 billion to the current $1 trillion in digital wallet enterprise value by 2030. Watch the video version here. Sources: ARK Investment Management LLC, 2023. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.

We are very excited to be joined today by one of the world’s leaders in scientific and biological research, Dr. Jonathan Weissman. After a breakdown of Jonathan’s professional background, we dive into CRISPR and how the genetic engineering tool can be used for drug development, disease discovery, and as a therapeutic treatment of its own. You’ll learn how our guest is using CRISPR in his lab and some of the solutions that he and his team have come up with for protein misfolding. Jonathan explains how his work has evolved beyond cancer, why he’s a fan of ex vivo lung perfusions (EVLPs), what needs to be done to bring new therapies and technologies to market quicker, and why he believes that there is no better time to be a young scientist than right now! “It’s an incredibly exciting time. Our fundamental understanding of biology, of who we are and where we came from is changing dramatically.” — Dr. Jonathan Weissman Key Points From This Episode: Introducing Dr. Jonathan Weissman and his professional background. The idea of programmable medicine and how CRISPR fits into drug development. Exploring the benefits and drawbacks of using CRISPR tools. How Jonathan has been implementing CRISPR in his lab. Why he thinks that his work is an important biological development. CRISPR as both a tool for discovery and a therapeutic treatment of its own. Our guest explains how we’ve evolved even beyond cancer. Some of the problems of protein misfolding (and Jonathan’s solutions). Taking a look at CRISPR delivery methods and how he sees these processes evolving. The ins and outs of EVLPs and why our guest is excited by this topic. What needs to be done to reduce the time to market for new therapies and technologies. Why scientific outreach is important and why it’s an exciting time to be a young scientist. Jonathan’s advice for future science leaders.

The podcast discusses how precision therapies target the root cause of diseases using innovative methods like AI, CRISPR gene editing, and DNA sequencing. These therapies offer personalized healthcare and could significantly impact the future of medicine.

Reducing complexity, increasing speed, enhancing the user interface, reducing costs, reducing waste, enhancing equality, and saving lives; this is the mission of Zipline. Today on the show, we are joined by Keller Rinaudo Cliffton, the co-founder of the company on a mission to provide the world with an autonomous drone logistics system that is incomparable to any other delivery service on the planet. Despite the enormous amount of skepticism they were up against, Keller and his team chose to turn science fiction into reality. Through delivering blood to hospitals in Rwanda, Zipline has been able to reduce the maternal mortality rate by 88%, and they have flown over 40 million miles for commercial purposes. In this episode, Keller talks about the variety of challenges that have made the Zipline mission far harder than they anticipated, their humble approach to product development, and what this groundbreaking business model means for the future of logistics and human kind. “Five and a half million kids lose their lives every year due to lack of access to basic medical products. A big part of that is logistics.” — @KellerRinaudo Key Points From This Episode: The motivation behind the founding of Zipline. What Zipline’s first year of operations in Rwanda consisted of. Why the assumption that uptake of advanced technology always occurs in developed countries first is incorrect. How Zipline has expanded its service since its founding. The alternative delivery options to Zipline (and why Zipline believes its service offers so much more value to its customers). Statistics that highlight the impact that Zipline has had on the Rwandan healthcare system. Skepticism that the Zipline idea was met with prior to its launch. Why naivete can be an entrepreneurial superpower. The number of autonomous miles that Zipline drones have flown for commercial purposes. Obstacles that Keller and his team have had to overcome to get Zipline to where it is today. An overview of the expertise on the Zipline team. Zipline’s approach to product development. How Zipline has helped to evolve aerospace regulations. Reasons for the drastic increase in demand for instant delivery. The problems with traditional delivery mechanisms and how Zipline is solving them.

Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change. To learn more, view Big Ideas 2023. This week’s Big Ideas Monday Mini Episode focuses on Autonomous Logistics. Autonomous logistics—including trucks, drones, and robots—should lower delivery costs and increase convenience. Based on our updated assumptions on pricing, ARK estimates that autonomous logistics revenue could scale from nearly zero today to $1-2 trillion by 2030. Autonomous delivery charges could range from $0.20 to $10 per trip. Watch the video version here.

Join us today for a conversation on the exciting progress and possibilities of genetics in pediatric care, with Dr. Caleb Bupp. Caleb is the Division Chief of Medical Genetics and Genomics at Spectrum Health and Helen DeVos Children’s Hospital, and we get to hear from him about his path into this role, and how he first discovered his passion for helping young ones. Our guest comments on the central themes of parental communication, cost reduction, and genetic exceptionalism before we delve into some of the most noteworthy points of progress in the pediatric field at the moment. We look at the Project Baby Bear and Project Baby Deer programs, and the important impact that the speed and timing of results can have on the care of kids, with Caleb explaining the societal norms and expectations around genetics and engagement with these datasets. He also raises some concerns about access to care and shares an inspiring success story from the last few years, so make sure to tune in to get it all. If you have a sick kid and you can do a test to figure out why they’re sick really fast, you give better care.” — Dr. Caleb Bupp Key Points From This Episode: Caleb takes us through his career journey and the roots of his interest in genetics and pediatrics. Reflection on the Concert Genetics Conference and Caleb’s involvement. Reducing costs and freeing up resources for more impactful care. Thoughts on the intangible value of providing comprehensive patient information for parents. Dr. Bupp weighs in on the topic of genetic exceptionalism. Surprising recent developments in fields of genetics and pediatrics. Potential challenges with the amounts of information that clinicians needs to process. Experiences and progress with the Project Baby Bear program. Caleb’s recent paper and presentation on the work at Project Baby Deer. The impact of earlier and faster intervention when treating children. How more proactive and effective screening can affect general societal health. Caleb shares the standout story of a patient with variants of uncertain significance and DFMO (difluoromethylornithine, a substance being studied in the treatment of cancer). Applying the principals of drug repurposing to other scenarios. Looking to the future and Caleb’s hopes for the short and long-term of the pediatric space.